Study for Children & Adolescent With Severe Asthma With an Eosinophilic Phenotype Treated With Mepolizumab

Inclusion Criteria

• •1. Patient who provides his/her written informed Consent to participate prior to commencing any study related activities.
• •2. Children \& Adolescent aged 6-17 years at mepolizumab initiation
• •3. Patient with a current clinical diagnosis of severe asthma (as per GINA / ATS / ERS / BTS criteria) and eosinophilic phenotype (as per mepolizumab licence) at mepolizumab initiation
• •4. Patient currently under treatment or who initiates treatment with mepolizumab at the inclusion visit based on national asthma guidelines.
• •5. Patient with relevant paper or electronic-based medical records available for 12-months prior to enrolment date/ index date (date of first mepolizumab injection) for clinically significant asthma exacerbation.